Literature DB >> 17993361

Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies.

Paul Appleby, Valerie Beral, Amy Berrington de González, Didier Colin, Silvia Franceschi, Adrian Goodhill, Jane Green, Julian Peto, Martyn Plummer, Siân Sweetland.   

Abstract

BACKGROUND: Combined oral contraceptives are classified by the International Agency for Research on Cancer as a cause of cervical cancer. As the incidence of cervical cancer increases with age, the public-health implications of this association depend largely on the persistence of effects long after use of oral contraceptives has ceased. Information from 24 studies worldwide is pooled here to investigate the association between cervical carcinoma and pattern of oral contraceptive use.
METHODS: Individual data for 16,573 women with cervical cancer and 35,509 without cervical cancer were reanalysed centrally. Relative risks of cervical cancer were estimated by conditional logistic regression, stratifying by study, age, number of sexual partners, age at first intercourse, parity, smoking, and screening.
FINDINGS: Among current users of oral contraceptives the risk of invasive cervical cancer increased with increasing duration of use (relative risk for 5 or more years' use versus never use, 1.90 [95% CI 1.69-2.13]). The risk declined after use ceased, and by 10 or more years had returned to that of never users. A similar pattern of risk was seen both for invasive and in-situ cancer, and in women who tested positive for high-risk human papillomavirus. Relative risk did not vary substantially between women with different characteristics.
INTERPRETATION: The relative risk of cervical cancer is increased in current users of oral contraceptives and declines after use ceases. 10 years' use of oral contraceptives from around age 20 to 30 years is estimated to increase the cumulative incidence of invasive cervical cancer by age 50 from 7.3 to 8.3 per 1000 in less developed countries and from 3.8 to 4.5 per 1000 in more developed countries.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17993361     DOI: 10.1016/S0140-6736(07)61684-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  111 in total

1.  Genetic variations in human papillomavirus and cervical cancer outcomes.

Authors:  Janet S Rader; Shirng-Wern Tsaih; Daniel Fullin; Miriam W Murray; Marissa Iden; Michael T Zimmermann; Michael J Flister
Journal:  Int J Cancer       Date:  2019-01-04       Impact factor: 7.396

Review 2.  Estrogen and ERalpha: culprits in cervical cancer?

Authors:  Sang-Hyuk Chung; Silvia Franceschi; Paul F Lambert
Journal:  Trends Endocrinol Metab       Date:  2010-04-22       Impact factor: 12.015

Review 3.  Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks.

Authors:  Jan Brynhildsen
Journal:  Ther Adv Drug Saf       Date:  2014-10

Review 4.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

5.  Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women.

Authors:  Anna-Barbara Moscicki; Yifei Ma; Charles Wibbelsman; Teresa M Darragh; Adaleen Powers; Sepideh Farhat; Stephen Shiboski
Journal:  Obstet Gynecol       Date:  2010-12       Impact factor: 7.661

6.  The contraceptive revolution: some excellent progress but work still to be done.

Authors:  Philip Hannaford; Toni Belfield
Journal:  Br J Gen Pract       Date:  2009-01       Impact factor: 5.386

7.  Do selective estrogen receptor modulators treat cervical precancer and cancer? Time to pool data from relevant trials.

Authors:  Philip E Castle
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

Review 8.  Human papillomavirus disease and vaccines in adolescents.

Authors:  Anna-Barbara Moscicki
Journal:  Adolesc Med State Art Rev       Date:  2010-08

Review 9.  Systematic literature reviews and meta-analyses: part 6 of a series on evaluation of scientific publications.

Authors:  Meike Ressing; Maria Blettner; Stefanie J Klug
Journal:  Dtsch Arztebl Int       Date:  2009-07-03       Impact factor: 5.594

10.  17β-hydroxysteroid dehydrogenase type Gene 1937 A > G Polymorphism as a Risk Factor for Cervical Cancer Progression in the Polish Population.

Authors:  Anna Lutkowska; Andrzej Roszak; Pawel P Jagodziński
Journal:  Pathol Oncol Res       Date:  2016-08-29       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.